CorMedix CRMD 深 沪

CorMedix Q3 Profit Soars As DefenCath Dialysis Demand Exceeds Expectations

CorMedix posts strong Q3 results with $104 million in revenue, higher DefenCath sales, and raises 2025 guidance following Melinta integration progress.

11-13 00:49

CorMedix inc. Announces Customer Implementation

CorMedix Inc. announced that its Large Dialysis Organization (LDO) customer has begun ordering and implementing DefenCath, targeting at least 50% more patients than previously planned. As a result, the company has amended its agreement with the LDO and raised its second quarter net sales guidance to $35 million to $40 million from $31 million.

06-23 11:30

CorMedix Inc. To Participate In The Jefferies Global Healthcare Conference

05-30 12:30

CorMedix Has Entered Into A Multi-Year Commercial Supply Contract With A Global Healthcare Company For The Supply Of DefenCath To Its Facilities In The U.S.

CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has entered into a multi-year commercial supply

2024-09-09 22:53

Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday

U.S. stocks were mostly higher, with the Dow Jones index gaining around 150 points on Monday. Shares of Galapagos NV (NASDAQ:GLPG) rose sharply during Monday's session after Ecor1 Capital reported a 9.9% stake in the company. Galapagos shares jumped 10% to $28.47 on Monday. Here are some other big s...

2024-08-26 21:59

Rodman & Renshaw Initiates Coverage On Cormedix with Buy Rating, Announces Price Target of $13

Rodman & Renshaw analyst Brandon Folkes initiates coverage on Cormedix (NASDAQ:CRMD) with a Buy rating and announces Price Target of $13.

2024-08-26 19:04

Needham Reiterates Buy on Cormedix, Maintains $10 Price Target

Needham analyst Serge Belanger reiterates Cormedix (NASDAQ:CRMD) with a Buy and maintains $10 price target.

2024-08-15 17:37